Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-19AI 评分30
吉利德口服 α4β7 抑制剂溃疡性结肠炎 II 期数据:缓解率高于 Entyvio
Gilead’s pill posts stronger colitis remission rates than Entyvio
AI 导读
吉利德口服 α4β7 抑制剂在溃疡性结肠炎 II 期剂量探索试验中,缓解率高于 Entyvio。公司计划明年启动该药的后期临床试验。
正文
Gilead Sciences is to start late-stage trials of its oral α4β7 inhibitor in ulcerative colitis next year, after data from a Phase 2 dose-finding trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news